Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 2
1948 1
1949 5
1950 1
1952 3
1953 3
1954 3
1955 2
1956 7
1957 9
1958 9
1959 5
1960 5
1961 7
1962 7
1963 2
1964 1
1965 4
1966 3
1967 3
1968 4
1969 6
1970 9
1971 6
1972 5
1973 9
1974 3
1975 1
1976 3
1977 4
1979 5
1980 7
1981 5
1982 3
1983 1
1984 5
1985 3
1986 4
1987 11
1988 2
1989 4
1990 10
1991 7
1992 5
1993 5
1994 7
1995 4
1996 6
1997 3
1998 5
1999 5
2000 1
2001 1
2002 1
2003 11
2004 3
2005 5
2006 4
2007 6
2008 4
2009 6
2010 6
2011 5
2012 11
2013 11
2014 17
2015 15
2016 9
2017 38
2018 33
2019 26
2020 31
2021 40
2022 31
2023 39
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

573 results

Results by year

Filters applied: . Clear all
Page 1
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Thieblemont C, et al. Among authors: lewis dj. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22. J Clin Oncol. 2023. PMID: 36548927 Free PMC article. Clinical Trial.
Merkel Cell Carcinoma.
Lewis DJ, Sobanko JF, Etzkorn JR, Shin TM, Giordano CN, McMurray SL, Walker JL, Zhang J, Miller CJ, Higgins HW 2nd. Lewis DJ, et al. Dermatol Clin. 2023 Jan;41(1):101-115. doi: 10.1016/j.det.2022.07.015. Epub 2022 Oct 28. Dermatol Clin. 2023. PMID: 36410971 Review.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Mato AR, et al. Among authors: lewis dj. Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5. Lancet. 2021. PMID: 33676628 Clinical Trial.
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Hutchings M, et al. Among authors: lewis dj. Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8. Lancet. 2021. PMID: 34508654 Clinical Trial.
Observation of Single-Top-Quark Production in Association with a Photon Using the ATLAS Detector.
Aad G, Abbott B, Abbott DC, Abeling K, Abidi SH, Aboulhorma A, Abramowicz H, Abreu H, Abulaiti Y, Abusleme Hoffman AC, Acharya BS, Achkar B, Adam L, Adam Bourdarios C, Adamczyk L, Adamek L, Addepalli SV, Adelman J, Adiguzel A, Adorni S, Adye T, Affolder AA, Afik Y, Agaras MN, Agarwala J, Aggarwal A, Agheorghiesei C, Aguilar-Saavedra JA, Ahmad A, Ahmadov F, Ahmed WS, Ahuja S, Ai X, Aielli G, Aizenberg I, Akbiyik M, Åkesson TPA, Akimov AV, Al Khoury K, Alberghi GL, Albert J, Albicocco P, Alconada Verzini MJ, Alderweireldt S, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi A, Alfonsi F, Alhroob M, Ali B, Ali S, Aliev M, Alimonti G, Allaire C, Allbrooke BMM, Allport PP, Aloisio A, Alonso F, Alpigiani C, Alunno Camelia E, Alvarez Estevez M, Alviggi MG, Amaral Coutinho Y, Ambler A, Amelung C, Ames CG, Amidei D, Amor Dos Santos SP, Amoroso S, Amos KR, Amrouche CS, Ananiev V, Anastopoulos C, Andari N, Andeen T, Anders JK, Andrean SY, Andreazza A, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Antrim DJA, Anulli F, Aoki M, Aparisi Pozo JA, Aparo MA, Aperio Bella L, Appelt C, Aranzabal N, Araujo Ferraz V, Arcangeletti C, Arce ATH, A… See abstract for full author list ➔ Aad G, et al. Among authors: lewis dj. Phys Rev Lett. 2023 Nov 3;131(18):181901. doi: 10.1103/PhysRevLett.131.181901. Phys Rev Lett. 2023. PMID: 37977601 Free article.
Adverse events in the digital age and where to find them.
Di Giovanni R, Cochrane A, Parker J, Lewis DJ. Di Giovanni R, et al. Among authors: lewis dj. Pharmacoepidemiol Drug Saf. 2022 Nov;31(11):1131-1139. doi: 10.1002/pds.5532. Epub 2022 Sep 9. Pharmacoepidemiol Drug Saf. 2022. PMID: 35996833 Review.
573 results